Saturday 17 October 2026
Export CHE’s income statement to Excel — free account
Chemed Corporation
CHE Healthcare Medical Care Facilities
Chemed Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 4.06% from fiscal 2024. In the quarter to June 2026, revenue grew 8.80%, EPS grew 42.8% and free cash flow fell 43.5%, each against the same quarter a year earlier. Dividend growth for twenty-five consecutive years, revenue growth for three.
512.38
3.06
−0.59%
Follow CHE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
23.50 | 23.19 | 20.54 | 23.37 |
P/S ratio |
2.55 | 2.43 | 2.03 | 2.36 | |
P/FCF ratio |
17.68 | 18.67 | 13.53 | 18.70 | |
P/Operating CF |
77.29 | 46.13 | 58.55 | 72.34 | |
P/B ratio |
5.99 | 6.29 | 6.09 | 7.39 | |
Price to Tangible BV |
19.84 | 26.83 | 64.51 | 116.84 | |
EV/Sales |
2.54 | 2.45 | 2.06 | 2.40 | |
EV/EBITDA |
15.43 | 15.34 | 13.31 | 15.00 | |
EV/Operating CF |
15.30 | 15.94 | 11.82 | 16.00 | |
EV/FCF |
17.61 | 18.75 | 13.74 | 19.02 | |
Quick Ratio |
1.18 | 0.90 | 0.72 | 0.72 | |
Current Ratio |
1.35 | 1.05 | 0.85 | 0.91 | |
Net Debt/EBITDA |
(1.42) | (0.64) | 0.73 | 0.94 | |
Debt/Assets |
0.00% | 0.00% | 5.94% | 8.86% | |
Debt/Equity |
0.00 | 0.00 | 0.11 | 0.17 | |
Asset Turnover |
1.49 | 1.58 | 1.56 | 1.57 | |
Operating CF/Net income |
1.30 | 1.74 | 1.33 | 1.25 | |
Capex/Depreciation |
(0.86) | (0.95) | (1.00) | (0.89) | |
Interest Coverage |
163.57 | 193.19 | 165.19 | 49.86 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
16.93% | 16.50% | 17.39% | 17.11% | |
Intangible Assets out of Total Assets |
0.46 | 0.49 | 0.50 | 0.49 | |
Share Based Compensation of Revenue |
0.94% | 1.58% | 1.62% | 1.68% | |
Graham Net Nets |
(0.02) | (0.04) | (0.08) | (0.07) | |
Graham Number |
179.06 | 168.04 | 160.18 | 168.14 | |
Earnings Yield |
4.25% | 4.31% | 4.87% | 4.28% | |
Free Cash Flow Yield |
5.65% | 5.36% | 7.39% | 5.35% | |
Revenue per Share |
43.41 | 44.40 | 48.08 | 51.10 | |
Operating CF per Share |
5.79 | 9.27 | 6.45 | 6.44 | |
Capex per Share |
(0.98) | (1.08) | (1.24) | (1.16) | |
Free Cash Flow per Share |
4.81 | 8.20 | 5.21 | 5.28 | |
Cash per Share |
9.01 | 5.18 | 1.23 | 3.05 | |
Shareholders Equity per Share |
74.80 | 68.02 | 62.01 | 63.04 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
74.80 | 68.02 | 62.01 | 63.04 | |
Free Cash Flow |
69.30 | 118.00 | 71.24 | 69.58 | |
Working Capital |
103.20 | 15.49 | (47.35) | (28.61) | |
Capital Expenditures |
(14.09) | (15.53) | (16.98) | (15.23) | |
Net Current Asset Value |
(151.69) | (256.17) | (413.76) | (457.84) | |
EV/EBIT |
18.26 | 18.30 | 15.99 | 17.87 | |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.02 | |
Price to Operating Income |
18.34 | 18.21 | 15.75 | 17.57 | |
| Other line items | |||||
Average Receivables |
206.03 | 176.87 | 250.68 | 186.76 | |
Average Payables |
46.52 | 54.30 | 56.70 | 67.79 | |
Average Inventory |
9.07 | 7.87 | 7.50 | 8.39 | |
Average Assets |
1,696.53 | 1,603.38 | 1,631.17 | 1,648.72 | |
Average Common Equity |
1,156.22 | 1,049.20 | 1,014.88 | 1,014.50 |
Columns are period end dates